Mylan Says It's Committed to King Deal  NEW YORK (Reuters) - Mylan Laboratories Inc. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=MYL.N target=/stocks/quickinfo/fullquote"&gt;MYL.N&lt;/A&gt; on  Wednesday said investor Carl Icahn's opposition to Mylan's  proposed purchase of King Pharmaceuticals Inc. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=KG.N target=/stocks/quickinfo/fullquote"&gt;KG.N&lt;/A&gt; does not  affect Mylan's commitment to complete the transaction.